Meningiomas
6
0
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
33%
2 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Measuring and Mapping Cognitive Decline After Brain Radiosurgery
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Effects of Scalp Nerve Blocks on Systemic Inflammation
SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors
Efficacy of Tranexamic Acid in Brain Tumor Resections